Phase I Study of Indibulin in Patients With Solid Tumors

Phase 1

Completed

• Conditions: Solid Tumors
• Interventions: Drug: indibulin

• Registration Number: NCT00591136
• Lead Sponsor: Alaunos Therapeutics

Brief Summary

Dose-finding and pharmacokinetic trial of orally administered Indibulin to patients with solid tumors.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-04
• Study First Submitted: 2007-12-26
• Study First Submitted QC: 2007-12-26
• Study First Posted: 2008-01-11
• Primary Completion: 2008-09
• Study Completion: 2008-09
• Status Verified: 2012-07
• Last Update Submitted: 2012-07-18
• Last Update Posted: 2012-07-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 47

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single Arm	indibulin	-

Primary Outcome Measures

Name	Time	Method
toxicities	4 months

Secondary Outcome Measures

Name	Time	Method
pharmacokinetics	4 months